Michael Thomas Crimmins

US Patent:

7320974, Jan 22, 2008

Filed:

Mar 23, 2006

Appl. No.:

11/389665

Inventors:

John W. Lampe - Cary NC, US
Robert Plourde, Jr. - Chapel Hill NC, US
Jin She - Chapel Hill NC, US
Jason L. Vittitow - Durham NC, US
Paul S. Watson - Carrboro NC, US
Michael T. Crimmins - Chapel Hill NC, US
David J. Slade - Durham NC, US

Assignee:

Inspire Pharmaceuticals, Inc. - Durham NC

International Classification:

A61K 31/351
A61K 31/357
C07D 309/06
C07D 313/02
C07D 313/16

US Classification:

51421109, 514450, 540451, 540456, 540468, 548182

Abstract:

The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

US Patent:

7666861, Feb 23, 2010

Filed:

Dec 4, 2007

Appl. No.:

11/950327

Inventors:

John W. Lampe - Cary NC, US
Robert Plourde, Jr. - Chapel Hill NC, US
Jin She - Chapel Hill NC, US
Jason L. Vittitow - Durham NC, US
Paul S. Watson - Carrboro NC, US
Michael T. Crimmins - Chapel Hill NC, US
David J. Slade - Durham NC, US

Assignee:

Inspire Pharmaceuticals, Inc. - Durham NC

International Classification:

A61K 31/351
A61K 31/357
C07D 309/06
C07D 313/02
C07D 313/16

US Classification:

51421109, 514450, 540451, 540456, 540468, 548182

Abstract:

The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

US Patent:

8039465, Oct 18, 2011

Filed:

Jan 28, 2010

Appl. No.:

12/695348

Inventors:

John W. Lampe - Cary NC, US
Robert Plourde, Jr. - Chapel Hill NC, US
Jin She - Chapel Hill NC, US
Jason L. Vittitow - Durham NC, US
Paul S. Watson - Carrboro NC, US
Michael T. Crimmins - Chapel Hill NC, US
David J. Slade - Durham NC, US

Assignee:

Inspire Pharmaceuticals, Inc. - Whitehouse Station NJ

International Classification:

A61K 31/54

US Classification:

5142272, 544122, 544123

Abstract:

The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

US Patent:

59731613, Oct 26, 1999

Filed:

Mar 17, 1997

Appl. No.:

8/818357

Inventors:

Michael T. Crimmins - Durham NC

Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

C07D27714
C07D26320
C07D27506

US Classification:

548188

Abstract:

Methods of synthesizing compounds of the Formula V: ##STR1## wherein X. sub. c is a chiral auxiliary, m is from 1 to 4, and R. sub. 8 is hydrogen or --OH, are provided. Additionally, methods of synthesizing compounds of the Formula XII: ##STR2## wherein m is from 1-4; B is hydrogen or a blocking group; and R. sub. 13 is a leaving group or a compound of formula R. sub. 14 --N--R. sub. 15 ; wherein R. sub. 14 is hydrogen or branched or straight-chain C1-C6 alkyl; and R. sub. 15 is hydrogen, C3-C8 cycloalkyl, or branched or straight-chain alkyl; are also provided. Novel compounds useful in the synthesis of cyclopentenes and carbocyclic nucleosides are further provided.